

Clinical Trial Protocol

Iranian Registry of Clinical Trials

27 Jul 2026

Comparison the Effect of Cinnarizine and Amitriptyline in Pediatric Migraine Prophylaxis of Children Referring to Children Medical Center Hospital: a Randomized Clinical Trial

Protocol summary

Study aim

Comparison the Effect of Cinnarizine and Amitriptyline in Pediatric Migraine Prophylaxis of Children Referring to Children Medical Center Hospital

Design

This randomized clinical trial, consist of two parallel intervention groups and each one contain 35. The Study is double blinded and the way of randomization is random letter. The phase of the study is: 3.

Settings and conduct

Children aged between 4 and 18 years, who refer to neurology clinic of children medical center hospital for their headaches and are diagnosed with migraine (if she/he be eligible for study) , are referred to one who has not any role in the treatment process. He will randomly divide patients into one of two intervention groups based on letter randomization method. Before starting treatment, patients will initially complete the headache checklist as a baseline information and then will start medication. During this time, headaches details (episode, duration, severity and ...) will be noted in a special checklist prepared for this purpose. Patients will be followed every month and finally after 3 months they will be visited again. Physician will not be aware of patients' groups till the end of the study.

Participants/Inclusion and exclusion criteria

Children with one or more migraine attack experience per month or severe dysfunction in daily or school activities and has not used prophylactic migraine therapy in one previous month and has not focal neurologic deficit and has not known concomitant serious diseases.

Intervention groups

Intervention group 1: Cinnarizine Intervention group 2: Amitriptyline

Main outcome variables

Frequency, severity and duration of headaches episodes

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20191112045413N1**

Registration date: **2020-01-24, 1398/11/04**

Registration timing: **registered_while_recruiting**

Last update: **2020-01-24, 1398/11/04**

Update count: **0**

Registration date

2020-01-24, 1398/11/04

Registrant information

Name

Mehrnaz Olfat

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 7703 7596

Email address

olfat.mehrnaz@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2019-12-06, 1398/09/15

Expected recruitment end date

2020-04-19, 1399/01/31

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparison the Effect of Cinnarizine and Amitriptyline in Pediatric Migraine Prophylaxis of Children Referring to Children Medical Center Hospital: a Randomized Clinical Trial

Public title

Comparison the Effect of Cinnarizine and Amitriptyline in Pediatric Migraine

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Having experienced one or more migraine attacks per month or severe dysfunction in daily and school activities

Exclusion criteria:

Use of prophylactic migraine therapy in at least one previous month Focal Neurologic Deficit Known concomitant serious diseases (hepatic, renal, etc)

Age

From **4 years** old to **18 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser

Sample size

Target sample size: **70**

Randomization (investigator's opinion)

Randomized

Randomization description

Random allocation: Patients will be randomly assigned to two groups of cinnarizine and amitriptyline. The random allocation method of these two groups is block randomization and block size is considered 6 persons and we are using Random allocation software for this process. This sequence will be kept secret with the clerk secretary. None of the participants in the study will be aware of the randomization list and for this purpose we will use color-numbered folders, which will be kept by the clerk secretary who is the only one that know about the allocation groups.

Blinding (investigator's opinion)

Double blinded

Blinding description

This is a double blind study. Patients and practitioners and annalist will be unaware of the type of treatment assigned. In order to blind the executive staffs, those applying the treatment will be different from those responsible for examining and evaluating patients. Drug packages will also be labeled according to a specific code. Only the clinic secretary will be informed of the type of drug that patients receive.

Placebo

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Tehran University of Medical Sciences

Street address

District 6, Keshavarz Boulevard and Ghods St. crossing. Main Office of Tehran University of Medical Sciences

City

Tehran

Province

Tehran

Postal code

1417653761

Approval date

2019-07-09, 1398/04/18

Ethics committee reference number

IR.TUMS.MEDICINE.REC.1398.334

Health conditions studied**1****Description of health condition studied**

میگرن

ICD-10 code

G43

ICD-10 code description

Migraine

Primary outcomes**1****Description**

Percent of patients who the severity of their headache episodes decreased to less than 50% of baseline

Timepoint

One month before to 3 months after initiation of treatment

Method of measurement

Visual Analogue Scale and Visual Pain Scale

2**Description**

Percent of patients who the frequency of their headache episodes decreased to less than 50% of baseline

Timepoint

One month before to 3 months after initiation of treatment

Method of measurement

By charting all the headache episodes by detail in the special checklist

3

Description

Percent of patients who the duration of their headache episodes decreased to less than 50% of baseline

Timepoint

One month before to 3 months after initiation of treatment

Method of measurement

By charting all the headache episodes by detail in the special checklist

Secondary outcomes

1

Description

Quality of life scoring

Timepoint

One month before to 3 months after initiation of treatment

Method of measurement

PedMIDAS questionnaire

Intervention groups

1

Description

First Intervention group: patients receiving Cinnarizine 25 mg, start with one half of tablet each night and after 10 days, increase to one complete tablet each night, for 3 consecutive months.

Category

Treatment - Drugs

2

Description

Second intervention group: patients receiving Amitriptyline 25 mg, start with one half of tablet each night and after 10 days, increase to one complete tablet each night, for 3 consecutive months.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Children Medical Center Hospital

Full name of responsible person

Mehrnaz Olfat

Street address

No. 62, Mohammad Gharib Street, Keshavarz Blvd.

City

Tehran

Province

Tehran

Postal code

1419733151

Phone

+98 21 6147 2751

Email

cmcpr@tums.ac.ir

Web page address

http://chmc.tums.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

chancellor for research and technology

Street address

District 6, Keshavarz Boulevard and Ghods St. crossing. Main Office of Tehran University of Medical Sciences

City

Tehran

Province

Tehran

Postal code

1417653761

Phone

+98 21 8163 3685

Fax

+98 21 8670 5503

Email

vcr@tums.ac.ir

Web page address

http://vcr.tums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Tehran University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Tehran University of Medical Sciences
Full name of responsible person
 Mehrnaz Olfat
Position
 Pediatric Resident
Latest degree
 Medical doctor
Other areas of specialty/work
 Pediatrics
Street address
 No. 14, Banaei Street, Davoud Armaghani Ave.,
 Damavand Blvd.
City
 Tehran
Province
 Tehran
Postal code
 1643814551
Phone
 +98 21 7703 7596
Fax
Email
 olfat.mehrnaz@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity
 Tehran University of Medical Sciences
Full name of responsible person
 Mehrnaz Olfat
Position
 Pediatric Resident
Latest degree
 Medical doctor
Other areas of specialty/work
 Pediatrics
Street address
 No. 14, Banaei Street, Davoud Armaghani Ave.,
 Damavand Blvd.
City
 Tehran
Province
 Tehran
Postal code
 1
Phone
 +98 21 7703 7596
Fax
Email
 olfat.mehrnaz@gmail.com

Person responsible for updating data

Contact

Name of organization / entity
 Tehran University of Medical Sciences

Full name of responsible person
 Mehrnaz Olfat
Position
 Pediatric Resident
Latest degree
 Medical doctor
Other areas of specialty/work
 Pediatrics
Street address
 No. 14, Banaei Street, Davoud Armaghani Ave.,
 Damavand Blvd.
City
 Tehran
Province
 Tehran
Postal code
 1643814551
Phone
 +98 21 7703 7596
Fax
Email
 olfat.mehrnaz@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

No - There is not a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

No - There is not a plan to make this available

Title and more details about the data/document

All the information about outcomes will be published

When the data will become available and for how long

6-12 months after publication

To whom data/document is available

Researcher of academic institute

Under which criteria data/document could be used

The data of our study will be accessible by other researchers, for conducting Meta-analysis

From where data/document is obtainable

No decision is made yet

What processes are involved for a request to access data/document

The researchers should explain the aims of their study.
 The request will be assessed by our team, and if we agree to the request, the requested data will be emailed.

Comments

No further explanation